4EEV

Crystal structure of c-Met in complex with LY2801653

Summary for 4EEV

Entry DOI	10.2210/pdb4eev/pdb
Descriptor	Hepatocyte growth factor receptor, N-(3-fluoro-4-{[1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yl]oxy}phenyl)-1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide (3 entities in total)
Functional Keywords	protein tyrosine kinase, transferase-transferase inhibitor complex, transferase/transferase inhibitor
Biological source	Homo sapiens (human)
Cellular location	Membrane; Single-pass type I membrane protein. Isoform 3: Secreted: P08581
Total number of polymer chains	1
Total formula weight	36486.11
Authors	Wang, Y.,Stout, S.L. (deposition date: 2012-03-28, release date: 2013-04-10, Last modification date: 2024-02-28)
Primary citation	Yan, S.B.,Peek, V.L.,Ajamie, R.,Buchanan, S.G.,Graff, J.R.,Heidler, S.A.,Hui, Y.H.,Huss, K.L.,Konicek, B.W.,Manro, J.R.,Shih, C.,Stewart, J.A.,Stewart, T.R.,Stout, S.L.,Uhlik, M.T.,Um, S.L.,Wang, Y.,Wu, W.,Yan, L.,Yang, W.J.,Zhong, B.,Walgren, R.A. LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models. Invest New Drugs, 31:833-844, 2013 Cited by PubMed: 23275061 DOI: 10.1007/s10637-012-9912-9 PDB entries with the same primary citation
Experimental method	X-RAY DIFFRACTION (1.8 Å)

Structure validation